Polarean Imaging PLC - London-based medical imaging technology developer - Says the US Centers for Medicare & Medicaid Services has established a new reimbursement code for Polarean’s Xenoview or ’xenon XE 129’ magnetic resonance imaging technology. Code ‘enables healthcare providers a path to bill for ’magnetic resonance imaging with [the] inhaled hyperpolarised xenon-129 contrast agent...including preparation and administration of agent’.’ Polarean expects to be informed of the new code’s payment level ‘in the coming weeks’.

Chief Executive Officer Christopher von Jako says: ‘We have been working diligently with CMS, our clinicians and hospital-based billing stakeholders over the past several months and view this as an important step towards enhancing accessibility to this innovative technology. We look forward to learning the payment details tied to the new code...as we continue to increase access to Xenoview MRI for patients suffering from ventilation-associated lung diseases.’

Current stock price: 16.41 pence, up 7.6% in London around midday on Tuesday

12-month change: down 74%

Copyright 2023 Alliance News Ltd. All Rights Reserved.